Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial

医学 焦磷酸钙 强的松 不利影响 痛风 关节炎 内科学 外科
作者
Tristan Pascart,P. Robinet,Sébastien Ottaviani,Rémi Leroy,N. Segaud,Aurore Pacaud,Agathe Grandjean,H. Luraschi,Thibault Rabin,Xavier Deplanque,Pierre Maciejasz,Fabien Visade,A Mackowiak,N. Baclet,Sylvestre Maréchaux,Antoine Lefebvre,Jean‐François Budzik,Thomas Bardin,Pascal Richette,Laurène Norberciak
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:5 (9): e523-e531 被引量:23
标识
DOI:10.1016/s2665-9913(23)00165-0
摘要

Background Acute calcium pyrophosphate crystal arthritis causes intense joint pain mainly affecting older people. Because guidance and evidence remain scarce, management of this disease relies on expert opinion. We therefore aimed to compare the safety and short-term equivalence of low-dose colchicine with oral prednisone in older patients with acute calcium pyrophosphate crystal arthritis. Methods We did an open-label, multicentre, randomised, trial (COLCHICORT) at six hospitals in Paris and northern France. We enrolled patients who were admitted to hospital who were 65 years or older and who presented with acute calcium pyrophosphate crystal arthritis with a symptom duration of less than 36 h. Diagnosis of calcium pyrophosphate crystal arthritis was made by the identification of calcium pyrophosphate crystals on synovial fluid analysis or typical clinical presentation (onset of joint pain and swelling). Key exclusion criteria included absence of calcium pyrophosphate crystals on synovial fluid analysis or a history of gout. Participants were randomly allocated (1:1), using a centralised electronic treatment group allocation module, to receive either colchicine 1·5 mg on day 1 and 1 mg on day 2 (ie, the colchicine group) or oral prednisone 30 mg on days 1 and 2 (ie, the prednisone group). The primary outcome was change in joint pain (measured by visual analogue scale [VAS] from 0 mm to 100 mm) at 24 h. Equivalence was determined whether the 95% CI of the between-group difference at 24 h was within the –13 mm to +13 mm margin in the per-protocol analysis. Adverse events were recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). This trial is completed and is registered with ClinicalTrials.gov, NCT03128905. Findings Between Feb 5, 2018, and May 7, 2022, 111 patients who were admitted to hospital were randomly assigned (57 [51%] to the colchicine group and 54 [49%] to the prednisone group). 95 (86%) of 111 patients were included in the per-protocol analysis (49 [52%] in the colchicine group and 46 [48%] in the prednisone group). The median age was 88·0 years (IQR 82·0–91·0) and 69 (73%) of 95 participants were women and 26 (27%) were men. Acute calcium pyrophosphate crystal arthritis affected mainly the knee in 46 (48%) of 95 participants, the wrist in 19 (20%), and the ankle in 12 (13%). Pain VAS at baseline was 68 mm (SD 17). At 24 h, change in pain VAS was –36 mm (SD 32) in the colchicine group and –38 mm (SD 23) in the prednisone group. The between-group difference in change in pain VAS at 24 h was –1 mm (95% CI –12 to 10), showing equivalence between the two drugs. In the colchicine group, 12 (22%) of 55 patients had diarrhoea, one (2%) had hypertension, and none had hyperglycaemia. In the prednisone group, three (6%) of 54 had diarrhoea, six (11%) had hypertension, and three (6%) had hyperglycaemia. No deaths occurred in the colchicine group; two deaths occurred in the prednisone group, which were deemed unrelated to prednisone (one due to infectious valvular endocarditis leading to heart failure, and one due to a stroke). Interpretation Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population. Funding French Inter-regional Hospital Program of Clinical Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大椒完成签到 ,获得积分10
2秒前
5秒前
7秒前
wisdom完成签到,获得积分10
7秒前
slayers发布了新的文献求助30
10秒前
11秒前
e746700020完成签到,获得积分10
12秒前
高兴尔冬完成签到,获得积分10
12秒前
李爱国应助不安的秋白采纳,获得10
14秒前
忧伤的步美完成签到,获得积分10
19秒前
小西完成签到 ,获得积分10
20秒前
郝老头完成签到,获得积分10
21秒前
13313完成签到,获得积分10
22秒前
su完成签到 ,获得积分10
23秒前
26秒前
31秒前
量子星尘发布了新的文献求助10
31秒前
slayers完成签到 ,获得积分10
31秒前
33秒前
知犯何逆完成签到,获得积分10
35秒前
Krsky完成签到,获得积分10
37秒前
ding应助不安的秋白采纳,获得10
38秒前
39秒前
41秒前
HHHAN发布了新的文献求助10
45秒前
威武的沂完成签到,获得积分10
50秒前
52秒前
53秒前
55秒前
笨笨青筠完成签到 ,获得积分10
58秒前
mengmenglv完成签到 ,获得积分0
58秒前
Tonald Yang完成签到 ,获得积分20
1分钟前
1分钟前
落后的怀梦完成签到 ,获得积分10
1分钟前
陈坤完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
斯文败类应助zgx采纳,获得10
1分钟前
默默完成签到 ,获得积分10
1分钟前
KY Mr.WANG完成签到,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022